ETRA Stock — Electra Therapeutics, Inc. Common stock

Electra Therapeutics, Inc. Common stock (ETRA)

Updated October 16, 2026.

ETRA is a Stock. Total return is -41.7% over the past 0.1 years, 42.0 points behind SPY at 0.3%.

Electra Therapeutics is a clinical-stage biotechnology company developing immunology and cancer therapies that target signal regulatory proteins. The company's lead program, ELA026, is a monoclonal antibody designed to treat secondary hemophagocytic lymphohistiocytosis, a life-threatening hyperinflammatory condition. The company does not currently distribute to shareholders and is oriented toward investors with a higher risk tolerance for early-stage development companies that may offer significant long-term capital appreciation potential if clinical programs advance successfully.

ETRA performance versus SPY

Price and return data through 2026-10-16.

Total return is -41.7% over the past 0.1 years, 42.0 points behind SPY at 0.3%.

ETRA key facts

Asset type

Stock

Asset class

Equity

Inception date

09/17/2026

Distribution frequency

None

Last close

$8.75 (as of 2026-10-16)

Market cap

$549,210,856

Average volume

1380472.0

Payout ratio

0.0%

EPS

$-2.59

How Dividend Vision calculates yield and returns

Distribution rate (the posted rate) uses calculation basis unavailable. Issuer rates can use a different denominator and date, including ex-date NAV. Trailing-12-month yield is the sum of split-adjusted cash distributions with ex-dates in the last 12 months, divided by the published price. It lags a recent raise or cut. Total return uses split-adjusted close with distributions reinvested on the ex-dividend date (a modeling convention, not the cash-settlement date) from the first stored bar on or after inception through the latest bar, compared with the same window on the benchmark. That is the security's total return, not your personal gain/loss.

Yield and safety methodology · Distribution rate methodology · Distribution Safety Score methodology

Sources and review

Primary sources: prices and distributions from Dividend Vision, derived from vendor EOD data.

Reviewed by Bert Sweet, CEO and Co-owner of Dividend Vision. Methodology: Distribution Safety Score.

ETRA risks and drawbacks

Total return has trailed SPY over the available window.

Who may consider ETRA — and who may not

It is a weaker fit for investors who need monthly cash flow (ETRA does not currently distribute); investors whose main goal is matching SPY total return. This is educational context, not a recommendation to buy or sell.

More on ETRA

• All tickers starting with E

Tagged: Healthcare.

Frequently asked questions